GLYCONEX INCORPORATION AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AND INDEPENDENT AUDITORS' REVIEW REPORT **SEPTEMBER 30, 2023 AND 2022**

For the convenience of readers and for information purpose only, the auditors' report and the accompanying

financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.



REPORT ON REVIEW OF FINANCIAL STATEMENTS

To GlycoNex Incorporation

Introduction

We have reviewed the accompanying consolidated balance sheets of GlycoNex Incorporation and its subsidiary (the "Group") as at September 30, 2023 and 2022, and the related consolidated statements of comprehensive income for the three months and nine months the ended, as well as the consolidated statements of changes in equity and of cash flows for the nine months then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" and International Accounting Standard 34, "Interim Financial Reporting" that came into effect as endorsed by the Financial Supervisory Commission. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as at September 30, 2023 and 2022, and of its consolidated financial performance for the three months and nine months then ended, and its consolidated cash flows for the nine months then ended in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" and International Accounting Standard 34, "Interim Financial Reporting" that came into effect as endorsed by the Financial Supervisory Commission.

PricewaterhouseCoopers, Taiwan November 9, 2023

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

GLYCONEX INCORPORATION AND SUBSIDIARY CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2023, DECEMBER 31, 2022 AND SEPTEMBER 30, 2022 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	ASSETS	eptember 30, 2 AMOUNT	<u>2023</u>	December AMOUNT			September 30, 2022 AMOUNT %			
Current assets										
1100	Cash and cash equivalents	6(1)	\$ 109,847	7	\$ 82,	187	5 \$	\$ 159,358	9	
1136	Financial assets at amortised cost	- 6(2)								
	current		626,965	39	596,	582 3:	5	572,332	32	
1170	Accounts receivable, net		1,211	-		46		80	-	
1200	Other receivables		15,427	1	4,3	325		3,224	-	
1220	Current income tax assets		209	-		99		161	-	
1410	Prepayments	6(3)	17,352	1	29,	178	2	33,980	2	
1470	Other current assets		 322			310		352		
11XX	Total current assets		 771,333	48	713,	127 42	2 _	769,487	43	
]	Non-current assets									
1517	Financial assets at fair value	6(4)								
	through other comprehensive									
	income - non-current		13,453	1	13,	518	l	13,251	1	
1600	Property, plant and equipment	6(5) and 8	811,145	51	989,	919 5	7	998,492	56	
1900	Other non-current assets		 5,789			384		437		
15XX	Total non-current assets		 830,387	52	1,003,	32158	3 _	1,012,180	57	
1XXX	Total assets		\$ 1,601,720	100	\$ 1,716,9	948 100) \$	\$ 1,781,667	100	

(Continued)

GLYCONEX INCORPORATION AND SUBSIDIARY CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2023, DECEMBER 31, 2022 AND SEPTEMBER 30, 2022 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

				September 30, 20		December 31, 2022		September 30	
	LIABILITIES AND EQUITY	Notes		AMOUNT	<u>%</u>	AMOUNT	<u>%</u>	AMOUNT	<u>%</u>
	Current liabilities								
2100	Current borrowings	6(7) and 8	\$	-	-	\$ 5,000	1	\$ 15,000	1
2120	Current financial liabilities at fair	6(9)							
	value through profit or loss			261	-	-	-	-	-
2130	Contract liabilities - current	6(18)		82	-	76	-	76	
2150	Notes payable			1,350	-	900	-	1,350	
2200	Other payables	6(8)		26,516	2	36,996	2	24,738	1
2230	Current tax liabilities			14,645	1	-	-	-	-
2300	Other current liabilities	6(10) and 8		212,082	13	1,512		435	
21XX	Total current liabilities		_	254,936	16	44,484	3	41,599	2
	Non-current liabilities								
2500	Non-current financial liabilities at fair	r 6(9)							
	value through profit or loss			-	-	274	-	312	-
2530	Corporate bonds payable	6(10) and 8		-	-	218,679	13	248,196	14
2600	Other non-current liabilities	6(11)		6,085	<u> </u>	7,900		9,053	1
25XX	Total non-current liabilities			6,085	<u> </u>	226,853	13	257,561	15
2XXX	Total liabilities			261,021	16	271,337	16	299,160	17
	Equity attributable to owners of								
	parent								
	Share capital	6(14)							
3110	Common stock			1,086,401	68	1,070,980	62	1,019,728	57
3130	Certificate of entitlement to new								
	shares from convertible bonds			-	-	11,685	1	51,282	3
	Capital surplus	6(15)							
3200	Capital surplus			374,857	23	587,473	34	568,644	31
	Accumulated deficit	6(16)							
3350	Accumulated deficit		(114,667)(7)(218,700)	(13)	(150,619)(8)
	Other equity interest	6(17)							
3400	Other equity interest		(5,892)	- (5,827)	-	(6,528) -
3XXX	Total equity			1,340,699	84	1,445,611	84	1,482,507	83
	Significant contingent liabilities and	9							·
	unrecognised contract commitments								
3X2X	Total liabilities and equity		\$	1,601,720	100	\$ 1,716,948	100	\$ 1,781,667	100

The accompanying notes are an integral part of these consolidated financial statements.

GLYCONEX INCORPORATION AND SUBSIDIARY CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, EXCEPT FOR LOSS PER SHARE AMOUNTS)

			Three months ended September 30		Nine mo	nths ended	September 30				
				2023		2022		2023		2022	
	Items	Notes	A	MOUNT	%	AMOUNT	%	AMOUNT	% /	AMOUNT	%
4000	Operating revenue	6(18)	\$	933		\$ 73		\$ 2,542	100 \$	28,435	100
5000	Operating costs	6(23)(24)	(423) (<u>45</u>) (21) (<u>29</u>) (1,547)(61)(14,661) (52)
5950	Gross profit		_	510	55	52	71	995	39	13,774	48
	Operating expenses	6(23)(24)									
6100	Selling expenses		(1,383)(148) (1,278) (1751)(4,193) (165) (3,308) (12)
6200	General and administrative										
	expenses		(10,904)(1169) (14,940) (20466) (35,489) (1396) (40,453) (142)
6300	Research and development										
	expenses		(56,784) (_	6086) (51,636) (154,515) (_	6079) (_	135,344) (<u>476</u>)
6000	Total operating expenses		(69,071)(7403) (67,854) (<u>194,197</u>) (<u>7640</u>) (179,105) (630)
6900	Operating loss		(68,561)(7348) (67,802) (92880) (193,202) (7601)(165,331) (582)
	Non-operating income and										
	expenses										
7100	Interest income	6(2)(19)		2,802	300	1,525	2089	6,564	258	2,732	10
7010	Other income	6(6)(20)		5,046	541	4,975	6815	16,338	643	14,770	52
7020	Other gains and losses	6(21)		2,047	220	985	1349	74,565	2933	-	-
7050	Finance costs	6(22)	(1,424) (<u>153</u>) (2,608) (<u>3572</u>) (4,287) (168) (2,790) (10)
7000	Total non-operating income										
	and expenses			8,471	908	4,877	6681	93,180	3666	14,712	52
7900	Loss before income tax		(60,090)(6440) (62,925) (86199) (100,022) (3935) (150,619) (530)
7950	Income tax expense	6(25)			<u> </u>	<u>-</u>	(14,645) (576)	<u> </u>	
8200	Net loss		(\$	60,090)(6440) (\$ 62,925)(86199) (\$ 114,667)(4511)(\$	150,619) (530)
	Other comprehensive (loss)										
	income										
	Components of other										
	comprehensive (loss) income										
	that will not be reclassified to										
	profit or loss										
8316	Unrealised (losses) gains from	6(4)(17)									
	investments in equity										
	instruments measured at fair										
	value through other			020) (00)	Φ 070	1202	d (5)	2) (4	054) (2.
0200	comprehensive income		(\$	829) (89)	<u>\$ 878</u>	1203 (<u>\$ 65</u>) (2)(\$	954) (3)
8300	Total other comprehensive (loss)		. Φ	020) (00)	Φ 070	1202	d (5) (2) (4	054) (2.
	income for the period		(\$	829) (<u>89</u>)	\$ 878	1203 (<u>\$ 65</u>) (2)(\$	954) (3)
8500	Total comprehensive loss for the										
	period		(\$	60,919)(6529) (\$ 62,047)(84996) (\$ 114,732)(4513) (\$	151,573) (533)
	Loss attributable to:										
8610	Owners of the parent		(<u>\$</u>	60,090)(6440) (\$ 62,925)(86199) (<u>\$ 114,667</u>) (4511) (\$	150,619) (530)
	Comprehensive loss attributable										
	to:										
8710	Owners of the parent		(\$	60,919)(6529) (\$ 62,047)(84996) (\$ 114,732)(<u>4513</u>) (<u>\$</u>	151,573) (533)
	Loss per share (in dollars)	6(27)									
9750	Basic loss per share		(\$		0.55) (0.64)(1.06)(\$		1.54)
9850	Diluted loss per share		(\$		0.55)(\$	0.64)(\$	1.06)(\$		1.54)

GLYCONEX INCORPORATION AND SUBSIDIARY CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

								Equi	ity attribi	utabl	e to owners o	f the pa	rent								
		Capital					Capital Reserves									Other Equity Interest					
	Notes	Common stock		Certificate of entitlement to new shares from convertible		Ad	ditional paid in capital	Stock warrants		Restricted stock to employees		Others		Accumulated		Unrealised losses on financial assets measured at fair value through other comprehensive income		Unearned compensation of restricted stock to employees			Total equity
Nine months ended September 30, 2022																					
Balance at January 1, 2022		\$	974,818	\$	-	\$	559,678	\$	-	\$	3,947	\$	9	(\$	172,645)	(\$	5,140)	(\$	1,734)	\$	1,358,933
Net loss for the period			_		_		_		-		-		_	(150,619)		_		_	(150,619)
Other comprehensive loss for the period	6(17)		-		-		-		-		-		-		-	(954)		-	(954)
Total comprehensive loss			-		-		_	-	_	_	-		_	(150,619)	(954)		_	(151,573)
Issuance of common stock for cash	6(14)		45,000				57,500				_		-							-	102,500
Compensation costs of common stock for cash	6(13)		-		-		1,835		-		-		-		-		-		-		1,835
Capital reserve used to offset against accumulated deficit	6(16)		_		_	(172,645)		_		-		_		172,645		-		_		-
Issuance of convertible bonds	6(10)		-		-		-	3.5	5,870		-		-		-		-		-		35,870
Conversion of convertible bonds	6(10)		-		51,282		95,210	(12	2,680)		-		-		-		-		-		133,812
Retirement of restricted stocks to employees	6(13)	(90)		-		-		-	(80)		-		-		-		170		-
Compensation costs of restricted stocks to employees	6(13)		-		_		-		_		-		-		-		_		1,130		1,130
Balance at September 30, 2022		\$1,	019,728	\$	51,282	\$	541,578	\$ 23	3,190	\$	3,867	\$	9	(\$	150,619)	(\$	6,094)	(\$	434)	\$	1,482,507
Nine months ended September 30, 2023																					
Balance at January 1, 2023		\$1,	070,980	\$	11,685	\$	563,323	\$ 20	0,300	\$	3,841	\$	9	(\$	218,700)	(\$	5,827)	\$	-	\$	1,445,611
Net loss for the period			-		_		-		-		_		_	(114,667)		-		_	(114,667)
Other comprehensive loss for the period	6(17)		-		-		-		-		-		-		-	(65)		-	(65)
Total comprehensive loss			-		-		-		-		_		_	(114,667)	(65)		-	(114,732)
Capital reserve used to offset against accumulated deficit	6(16)		_		_	(218,700)		_				_		218,700		-				
Conversion of convertible bonds	6(10)		15,421	(11,685)		7,007	(923)		-		-		-		-		-		9,820
Balance at September 30, 2023		\$1,	086,401	\$	-	\$	351,630	\$ 19	9,377	\$	3,841	\$	9	(\$	114,667)	(\$	5,892)	\$		\$	1,340,699

GLYCONEX INCORPORATION AND SUBSIDIARY CONSOLIDATED STATEMENTS OF CASH FLOWS

NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Notes				Nine months ended September 30						
Section Sect		Notes		2023		2022				
Section Sect										
Adjustments to reconcile profit (loss) Depreciation 6(323) 22,812 29,768 Amortisation 6(23) 932 391 Interest expense 6(22) 4,287 2,792 Compensation costs of restricted stocks to employees 6(19) (6,564) (2,732) Compensation costs of restricted stocks to employees 6(13) - (1,130) Compensation costs of restricted stocks to employees 6(13) - (73,812) - (1,130) Compensation costs of restricted stocks to employees 6(13) - (73,812) - (1,230) Compensation costs of restricted stocks to employees 6(13) - (73,812) - (1,230) Compensation costs of restricted stocks to employees 6(13) - (73,812) - (1,230) Compensation costs of restricted stocks to employees 6(13) - (73,812) - (1,230) Compensation costs of restricted stocks to employees 6(13) - (73,812) - (1,230) Compensation costs of restricted stocks to employees 6(13) - (73,812) - (1,230) Compensation costs of restricted stocks to employees 6(13) - (73,812) - (1,230) Compensation costs of restricted stocks to employees 6(13) - (73,812) - (1,230) Compensation costs of restricted stocks to employees 6(13) - (1,230) - (1,230) Compensation costs of restricted stocks to employees 6(13) - (1,230) - (1,230) Compensation costs of restricted stocks to employees 6(13) - (1,230) - (1,230) Compensation costs of restricted stocks of the stocks										
Adjustments to reconcile profit (loss)			(\$	100,022)	(\$	150,619)				
Depreciation	3									
Manorisation										
Interest expense 6(22)	-									
Interest income										
Compensation costs of control chocks to employees 6(13) Can on disposal of property, plan and equipment 6(21) (73,812) Can on disposal of property, plan and equipment 6(21) (73,812) Changes in operating assets and liabilities Changes in operating assets Accounts receivable, net (10,888) (2,078, 81, 82, 82, 82, 82, 82, 82, 82, 82, 82, 82	•	* *								
Compensation costs of common stock for cash G(13) Gain on disposal of property, plan and equipment G(21) (73,812) (73,81		6(19)	(6,564)	(2,732)				
Changes in operating assets and liabilities				-						
Changes in operating assets and liabilities Changes in operating assets Changes in operating liabilities Changes in operating liabili		* *		-		1,835				
Changes in operating assets		6(21)	(73,812)		-				
Accounts receivables, net (1,165) 2700 Other receivables (10,888) (2,078) Prepayments (12,126 (8,454) Other current assets (12,126 (8,454) Other current assets (12,126 (8,454) Other current assets (12,126 (8,454) Other current liabilities Contract liabilities - current (16,500 (16,50										
Other receivables (10,888) (2,078) Prepayments 12,126 (8,454) Other current assets (12) (212) Changes in operating liabilities 8 Contract liabilities - current 6 - Notes payable 450 (10,937) (2,139) Other payables (10,937) (1,000) (1,088) Other current liabilities (10,200) (1,088) Other non-current liabilities (163,899) (1026,514) Cash outflow generated from operations (163,899) (1026,514) Interest paid (1,569) (1,060) Income tax paid (10,000) Net cash flows used in operating activities (19,128) (125,070) Seash outflow of property, plant and equipment 6(3) Increase in financial assets measured at amortised cost (30,383) (365,806) Acquisition of property, plant and equipment 6(3) 337,463) Increase in financial assets measured at amortised cost (3,998) - Increase in financial assets measured at amortised cost (30,383) (365,806) Increase in offinancial assets measured at amortised cost (3,998) - <tr< td=""><td></td><td></td><td></td><td></td><td></td><td></td></tr<>										
Prepayments 12,126 (8,454) Other current assets (12) (212) Changes in operating liabilities Tontract liabilities - current 6 - Notes payable 450 450 Other payables (10,937) 2,139 Other ourrent liabilities (10,020) (10,885) Other ourrent liabilities (163,899) (106,514 Other ourrent liabilities (32,000) (10,000) Cash outflow generated from operations (163,899) (106,514 Interest received (3,500) (2,425 Interest paid (1,569) (10,000) Income tax refund (10,000) Income tax paid (10,000) Net cash flows used in operating activities (30,383) (365,806) Acquisition of property, plant and equipment (30,383) (365,806) Acquisition of property, plant and equipment (30,383) (365,806) Acquisition of property, plant and equipment (shown as other non-current assets) (30,383) (365,806) Increase in prepayments for equipment (shown as other non-current assets) (770) (56 Increase in other non-current assets (3798) (36,900) N	Accounts receivable, net		(1,165)		270				
Other current assets (12) (212) Clanges in operating liabilities - - Notes payable 450 450 Other payables (10,937) 2,139 Other payables (10,207) 1,088) Other current liabilities (1,020) (1,088) Other non-current liabilities (163,899) (126,514) Cash outflow generated from operations (163,899) (126,514) Interest received (1,569) (1,569) (1,600) Increase in General Rows used in operating activities (1,599) (1,600) 1 1,600) 1,600	Other receivables		(10,888)	(2,078)				
Changes in operating liabilities 6	Prepayments			12,126	(8,454)				
Contract liabilities - current	Other current assets		(12)	(212)				
Notes payables 450 Other payables (10,937) 2,139 Other current liabilities (10,937) 1,088 Other non-current liabilities (22) 104 Cash outflow generated from operations (163,899) 126,514 Interest received 6,350 2,425 Interest paid (15,699) 1,060 Income tax refund - 79 Income tax paid (10) - Net cash flows used in operating activities (15,128) (125,070) CASH FLOWS FROM INVESTING ACTIVITIES 159,128 (125,070) Increase in financial assets measured at amortised cost (30,383) 365,806 Acquisition of property, plant and equipment 6(8) 7,232 8427 Proceeds from disposal of property, plant and equipment 6(5) 37,463 - Increase in prepayments for equipment (shown as other non-current assets) (770) 6 (Increase) decrease in refundable deposits (shown as other non-current assets) (770) 6 Increase in other non-current assets (1,569) (560)	Changes in operating liabilities									
Other payables (10,937) (1,088) Other current liabilities (1,000) (1,088) Other non-current liabilities (92) (104) Cash outflow generated from operations (163,899) (126,514) Interest received 6,350 (2,425) Interest paid (1,569) (1,060) Income tax refund - 79 Net cash flows used in operating activities (159,128) (125,070) CASH FLOWS FROM INVESTING ACTIVITIES (30,383) (365,866) Increase in financial assets measured at amortised cost (30,383) (365,866) Acquisition of property, plant and equipment 6(8) (7,232) (8,427) Proceeds from disposal of property, plant and equipment of (5) (237,463) - 2 Increase in prepayments for equipment (shown as other non-current assets) (3,998) - 2 (Increase) decrease in refundable deposits (shown as other non-current assets) (770) 6 Increase in other non-current assets (770) 6 Increase in other some stock for cash (shown as other non-current assets) (770) 6 Increase in short-term loans 6(14) - 2 103,500 Cost on issuance of common s	Contract liabilities - current			6		-				
Other current liabilities 1,020 (1,088) Other non-current liabilities 92 (104) Cash outflow generated from operations 163,899 (126,514) Interest received 6,350 (2,425) Interest paid 1,569 (1,569) (1,600) Income tax refund 2 (10) (10) (10) Net cash flows used in operating activities 159,128 (125,070) CASH FLOWS FROM INVESTING ACTIVITES (30,383) (365,806) Increase in financial assets measured at amortised cost (30,383) (365,806) Acquisition of property, plant and equipment (6(5) (237,463) (237,463) 2 (10) (237,463) Increase in prepayments for equipment (shown as other non-current assets) (770) (66) (Increase) decrease in refundable deposits (shown as other non-current assets) (770) (66) (Increase) decrease in other non-current assets (770) (66) (Increase) of common stock for cash 6(14) (770) (374,887) CASH FLOWS FROM FINANCING ACTIVITES 1 (700) (374,887) Issuance of common stock for cash (shown as deduction of capital reserve) - (1,000) Increase in short-term loans 6(29) (10,000 (15,000) (46,000) Decrease in short-term loans 6(29) (15,000 (15,000) (46,000)	Notes payable			450		450				
Other current liabilities (1,020) (1,088) Other non-current liabilities (92) (104) Cash outflow generated from operations (163,899) (126,514) Interest received 6,350 (2,425) Interest paid (1,569) (1,060) Income tax refund (10) (10) Net cash flows used in operating activities (10) (10) CASH FLOWS FROM INVESTING ACTIVITIES Increase in financial assets measured at amortised cost (30,383) (365,806) Acquisition of property, plant and equipment 6(8) (7,232) (8,427) Proceeds from disposal of property, plant and equipment 6(5) (337,463) 2 Increase in prepayments for equipment (shown as other non-current assets) (3,998) - (Increase) decrease in refundable deposits (shown as other non-current assets (770) 6 Increase in other non-current assets (770) 6 Net eash flows from (used in) investing activities 13,560 (374,887) CASH FLOWS FROM FINANCING ACTIVITIES 103,500 Issuance of common stock for eash (shown as deduction of capital reserve) 103,500 Obecrease in short-term loans <	Other payables		(10,937)		2,139				
Other non-current liabilities (92 (104 (Cash outflow generated from operations (163,899) (126,514 (Interest received (6,350 2,425 (Interest paid (1,569 (1,060 () Income tax paid (10 () 2 Net cash flows used in operating activities (159,128 () 125,070 () CASH FLOWS FROM INVESTING ACTIVITIES (30,383 () 365,806 () Increase in financial assets measured at amortised cost (30,383 () 365,806 () Acquisition of property, plant and equipment 6(5) 237,463 () 8,427 () Proceeds from disposal of property, plant and equipment (6(5) 237,463 () - Increase in prepayments for equipment (shown as other non-current assets) (3,998 () - (Increase) decrease in refundable deposits (shown as other non-current assets) (770 () 66 () Net cash flows from (used in) investing activities 193,511 () 374,887 () Cast FLOWS FROM FINANCING ACTIVITIES 193,500 () 61,000 () <td>Other current liabilities</td> <td></td> <td>(</td> <td></td> <td>(</td> <td>1,088)</td>	Other current liabilities		((1,088)				
Cash outflow generated from operations (163,899) (126,514) Interest received 6,350 (2,425) Interest paid (1,569) (1,060) Income tax refund - 79 Income tax paid (10) (159,128) (125,070) Net cash flows used in operating activities (159,128) (125,070) CASH FLOWS FROM INVESTING ACTIVITIES (30,383) (365,806) Increase in financial assets measured at amortised cost (30,383) (365,806) Acquisition of property, plant and equipment 6(28) (7,232) (34,827) Proceeds from disposal of property, plant and equipment (65) (237,463) (2.27) - 2 Increase in prepayments for equipment (shown as other non-current assets) (770) (600) (Increase) decrease in refundable deposits (shown as other non-current assets) (770) (600) Net cash flows from (used in) investing activities 193,511 (3374,887) Cost on issuance of common stock for cash (shown as deduction of capital reserve) (1,569) (600) Increase in short-term loans 6(29) (15,000) (10,000) Decrease in short-term loans 6(29) (15,000) (46,000) Decrease in short-term loans 6(29) (17,000) (17,000) Decrease in short-term loans<	Other non-current liabilities		Ì		(
Interest paid	Cash outflow generated from operations		((
Interest paid (1,569) (1,060) Income tax refund (1,569) (1,060) Income tax paid (10) 79 Income tax paid (10) 79 Income tax paid (159,128) (125,070) Increase in flows used in operating activities (159,128) (125,070) Increase in financial assets measured at amortised cost (30,383) (365,806) Acquisition of property, plant and equipment 6(28) (7,232) (8,427) Recase in prepayments for equipment (shown as other non-current assets) (3,998) -					`					
Income tax refund			((
Income tax paid (10)	•			-,,						
Net cash flows used in operating activities			(10)		-				
CASH FLOWS FROM INVESTING ACTIVITIES Increase in financial assets measured at amortised cost (*		((125 070)				
Increase in financial assets measured at amortised cost (30,383) (365,806) Acquisition of property, plant and equipment 6(28) (7,232) (8,427) Proceeds from disposal of property, plant and equipment 6(5) 237,463 - Increase in prepayments for equipment (shown as other non-current assets) (3,998) - (Increase) decrease in refundable deposits (shown as other non-current assets) (770) 6 Increase in other non-current assets (770) 6 Increase in other non-current assets (770) 6 Increase in other non-current assets (770) 6 Increase in other non-current assets (770) 6 Increase in other non-current assets (770) 6 Increase in other non-current assets (770) 6 Increase in other non-current assets (770) 6 Increase of common stock for cash 6 193,511 (374,887) CASH FLOWS FROM FINANCING ACTIVITIES				137,120	\	123,070				
Acquisition of property, plant and equipment 6(28) (7,232) (8,427) Proceeds from disposal of property, plant and equipment 6(5) 237,463 - Increase in prepayments for equipment (shown as other non-current assets) (3,998) - (3,9			(30 383)	(365 806)				
Proceeds from disposal of property, plant and equipment 6(5) 237,463 - Increase in prepayments for equipment (shown as other non-current assets) (3,998) - (Increase) decrease in refundable deposits (shown as other non-current assets) (770) 6 Increase in other non-current assets (1,569) (660) Net cash flows from (used in) investing activities (1,569) (660) Net cash flows from (used in) investing activities (1,569) (660) Net cash flows from function activities (1,569) (660) CASH FLOWS FROM FINANCING ACTIVITIES Issuance of common stock for cash (shown as deduction of capital reserve) (1,000) Increase in short-term loans (6(29) (15,000) (46,000) Decrease in short-term loans (6(29) (15,000) (46,000) (Decrease) increase in deposits received (shown as other non-current liabilities) (1,723) 293 Issuance of convertible bonds (6(10) - 420,630) Cost on issuance of convertible bonds (6(10) - 420,630) Net cash flows (used in) provided by financing activities (6,723) 534,248 Net increase in cash and cash equivalents (27,660) 34,291 Cash and cash equivalents at beginning of period		6(28)	((
Increase in prepayments for equipment (shown as other non-current assets) (3,998) - (Increase) decrease in refundable deposits (shown as other non-current assets) (770) 6 (770) 6 (1,569) (660)			((0,427)				
Increase of cerease in refundable deposits (shown as other non-current assets)		0(3)		237,403		-				
(Increase) decrease in refundable deposits (shown as other non-current assets) (770) 6 Increase in other non-current assets (1,569) 660) Net cash flows from (used in) investing activities 193,511 (374,887) CASH FLOWS FROM FINANCING ACTIVITIES 103,500 Issuance of common stock for cash 6(14) - (1,000) Cost on issuance of common stock for cash (shown as deduction of capital reserve) - (1,000) Increase in short-term loans 6(29) 10,000 (15,000) 61,000) Decrease in short-term loans 6(29) (15,000) 46,000) (Decrease) increase in deposits received (shown as other non-current liabilities) (1,723) 293 Issuance of convertible bonds 6(10) - (4,175) Net cash flows (used in) provided by financing activities (6,723) 534,248 Net increase in cash and cash equivalents 27,660 34,291 Cash and cash equivalents at beginning of period 82,187 125,067			(3 008)						
non-current assets (770) 6 Increase in other non-current assets (1,569) (660) Net cash flows from (used in) investing activities 193,511 (374,887) CASH FLOWS FROM FINANCING ACTIVITIES Issuance of common stock for cash 6(14) - 103,500 Cost on issuance of common stock for cash (shown as deduction of capital reserve) - 1,000 Increase in short-term loans 6(29) 10,000 61,000 Decrease in short-term loans 6(29) (15,000) (46,000) (Decrease) increase in deposits received (shown as other non-current liabilities) (1,723) 293 Issuance of convertible bonds 6(10) - 1 420,630 Cost on issuance of convertible bonds 6(10) - 1 420,630 Cost on issuance of convertible bonds 6(10) - 2 420,630 Net cash flows (used in) provided by financing activities (6,723) 534,248 Net increase in cash and cash equivalents 27,660 34,291 Cash and cash equivalents at beginning of period 82,187 125,067			(3,990)		-				
Increase in other non-current assets			,	770)		6				
Net cash flows from (used in) investing activities 193,511 (374,887) CASH FLOWS FROM FINANCING ACTIVITIES 103,500 Issuance of common stock for cash 6(14) - 103,500 Cost on issuance of common stock for cash (shown as deduction of capital reserve) - (1,000) Increase in short-term loans 6(29) 10,000 61,000 Decrease in short-term loans 6(29) (15,000) 46,000) (Decrease) increase in deposits received (shown as other non-current liabilities) (1,723) 293 Issuance of convertible bonds 6(10) - 420,630 Cost on issuance of convertible bonds 6(10) - 4,175) Net cash flows (used in) provided by financing activities (6,723) 534,248 Net increase in cash and cash equivalents 27,660 34,291 Cash and cash equivalents at beginning of period 82,187 125,067	,		(·	(
CASH FLOWS FROM FINANCING ACTIVITIES Issuance of common stock for cash 6(14) - 103,500 Cost on issuance of common stock for cash (shown as deduction of capital reserve) - (1,000) Increase in short-term loans 6(29) 10,000 61,000 Decrease in short-term loans 6(29) (15,000) 46,000) (Decrease) increase in deposits received (shown as other non-current liabilities) (1,723) 293 Issuance of convertible bonds 6(10) - 420,630 Cost on issuance of convertible bonds 6(10) - (4,175) Net cash flows (used in) provided by financing activities (6,723) 534,248 Net increase in cash and cash equivalents 27,660 34,291 Cash and cash equivalents at beginning of period 82,187 125,067			(·	`					
Issuance of common stock for cash 6(14) - 103,500 Cost on issuance of common stock for cash (shown as deduction of capital reserve) - (1,000) Increase in short-term loans 6(29) 10,000 (61,000) Decrease in short-term loans 6(29) (15,000) (46,000) (Decrease) increase in deposits received (shown as other non-current liabilities) (1,723) 293 Issuance of convertible bonds 6(10) - (420,630 Cost on issuance of convertible bonds 6(10) - (4,175) Net cash flows (used in) provided by financing activities (6,723) 534,248 Net increase in cash and cash equivalents 27,660 34,291 Cash and cash equivalents at beginning of period 82,187 125,067	` / / · ·		-	193,511	(3/4,88/_)				
Cost on issuance of common stock for cash (shown as deduction of capital reserve) $ \begin{array}{c} - & (& 1,000) \\ 1,000 & 61,000 \\ 10,000 & 61,000 \\ 0 & 15,000) & (& 46,000) \\ 0 & (& 15,000) & (& 46,000) \\ 0 & (& 15,000) & (& 46,000) \\ 0 & (& 1,723) & 293 \\ 0 & ($		((14)				102 500				
capital reserve) $ \begin{array}{ccccccccccccccccccccccccccccccccccc$		` '		-		103,500				
Increase in short-term loans $6(29)$ $10,000$ $61,000$ Decrease in short-term loans $6(29)$ $(15,000)$ $(46,000)$ (Decrease) increase in deposits received (shown as other non-current liabilities) $(17,23)$ 293 Issuance of convertible bonds $6(10)$ $ 420,630$ Cost on issuance of convertible bonds $6(10)$ $ (41,175)$ Net cash flows (used in) provided by financing activities (610) $ (67,23)$ $67,000$ Net increase in cash and cash equivalents (610) $67,000$ $61,00$	· · · · · · · · · · · · · · · · · · ·				,	1 000 \				
Decrease in short-term loans	± /	((20)		10.000	(
(Decrease) increase in deposits received (shown as other non-current liabilities) ($1,723$) 293 Issuance of convertible bonds $6(10)$ - $420,630$ Cost on issuance of convertible bonds $6(10)$ - $(4,175)$ Net cash flows (used in) provided by financing activities ($6,723$) $534,248$ Net increase in cash and cash equivalents $27,660$ $34,291$ Cash and cash equivalents at beginning of period $82,187$ $125,067$		* *								
non-current liabilities)($1,723$) 293 Issuance of convertible bonds $6(10)$ - $420,630$ Cost on issuance of convertible bonds $6(10)$ -($4,175$)Net cash flows (used in) provided by financing activities($6,723$) $534,248$ Net increase in cash and cash equivalents $27,660$ $34,291$ Cash and cash equivalents at beginning of period $82,187$ $125,067$		6(29)	(15,000)	(46,000)				
Issuance of convertible bonds $6(10)$ - $420,630$ Cost on issuance of convertible bonds $6(10)$ -($4,175$)Net cash flows (used in) provided by financing activities($6,723$) $534,248$ Net increase in cash and cash equivalents $27,660$ $34,291$ Cash and cash equivalents at beginning of period $82,187$ $125,067$				4 500 :		200				
Cost on issuance of convertible bonds $6(10)$ - $($ $4,175$)Net cash flows (used in) provided by financing activities $($ $6,723$) $534,248$ Net increase in cash and cash equivalents $27,660$ $34,291$ Cash and cash equivalents at beginning of period $82,187$ $125,067$			(1,723)						
Net cash flows (used in) provided by financing activities(6,723)534,248Net increase in cash and cash equivalents27,66034,291Cash and cash equivalents at beginning of period82,187125,067		` /		-						
Net increase in cash and cash equivalents27,66034,291Cash and cash equivalents at beginning of period82,187125,067		6(10)		<u> </u>	(
Cash and cash equivalents at beginning of period 82,187 125,067	, ,,,		(
Cash and cash equivalents at end of period \$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\										
	Cash and cash equivalents at end of period		\$	109,847	\$	159,358				